Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot multiple sclerosis (MS) imaging study conducted with Massachusetts General Hospital, and preliminary PET imaging data are showing encouraging signals in acute MS lesions. The company announced the progress, highlighting that the novel imaging technique is designed to distinguish demyelinated nerve fibers that may still be viable from permanent nerve damage, potentially offering a more precise way to measure myelin loss and repair.
These findings are directly relevant to Lucid-MS, the company's investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation. A more precise imaging tool and a drug candidate designed to address the underlying cause of MS make for a compelling combination. Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions.
The study's preliminary results could have significant implications for MS research and treatment. Current imaging methods often fail to differentiate between reversible demyelination and permanent axonal damage, limiting the ability to monitor disease progression and response to therapy. If validated, this new PET imaging technique could become a crucial biomarker for clinical trials, enabling more efficient evaluation of remyelinating therapies such as Lucid-MS.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
The company has also invented unbuzzd, a product aimed at reducing alcohol intoxication, and spun out its OTC version to Unbuzzd Wellness Inc. (UWI), retaining a 19.84% ownership stake as of March 31, 2026. The agreement with UWI includes royalty payments of 7% of sales until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
For investors, the progress in the imaging study is a positive signal for the company's pipeline. The ability to accurately measure myelin repair could accelerate the development of Lucid-MS and improve the chances of regulatory approval. The latest news and updates relating to QNTM are available in the company's newsroom at https://nnw.fm/QNTM.
The full article discussing these developments can be viewed at https://nnw.fm/fsDHa.
